Enhertu

Active Ingredient(s): Fam-trastuzumab Deruxtecan-nxki
FDA Approved: * December 20, 2019
Pharm Company: * DAIICHI SANKYO
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Enhertu Overview

Trastuzumab deruxtecan also known as fam-trastuzumab deruxtecan and sold under the brand name Enhertu, is a medication used for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.[1] Contents 1 Overview 2 Side effects and label warnings 3 History 4 References 5 Further...

Read more Enhertu Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Trastuzumab_deruxtecan

Recent Enhertu Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Fam-trastuzumab Deruxtecan-nxki
  • Injection: 100mg, 150mg, 420mg, 420mg/vial, 440mg, 600mg + 10000units
  • Vial: 100mg, 160mg, 21mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Enhertu: (1 result)

Sorted by National Drug Code
  • 65597-406 Enhertu 100 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Daiichi Sankyo Inc.

Other drugs which contain Fam-trastuzumab Deruxtecan-nxki or a similar ingredient: (12 results)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 20 September 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA